Indication
Major
42 clinical trials
44 products
2 drugs
Product
NEUROPHARMAGENProduct
Desvenlafaxine succinateClinical trial
A Multicenter, Randomized, 8-Week Double-Blind Acute Phase Followed By a 6-Month Continuation Phase (Open-Label Or Double-Blind) Study to Evaluate the Efficacy, Safety, and Tolerability of DVS SR Versus Escitalopram in Postmenopausal Women With Major Depressive DisorderStatus: Completed, Estimated PCD: 2008-02-01
Clinical trial
Randomised, Controlled, Parallel Clinical Trial on the Efficacy of Pharmacogenetic Information Obtained With NEUROFARMAGEN in the Treatment of Patients With Mental DisordersStatus: Completed, Estimated PCD: 2015-10-01
Product
Treatment As UsualProduct
EscitalopramProduct
SAGE-217Clinical trial
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive DisorderStatus: Completed, Estimated PCD: 2019-09-24
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)Status: Completed, Estimated PCD: 2023-09-29
Product
PlaceboProduct
TNX-601Clinical trial
A Phase 3, Randomized, Double-Blind Study Comparing the Efficacy and Safety of SAGE-217 Plus an Antidepressant Versus Placebo Plus an Antidepressant in Adults With Major Depressive DisorderStatus: Completed, Estimated PCD: 2021-10-25
Product
CitalopramProduct
DuloxetineProduct
DesvenlafaxineProduct
Matching PlaceboProduct
SertralineClinical trial
A Phase II, 6-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial With a Quetiapine Arm to Evaluate the Efficacy, Tolerability and Safety of Oral BI 1358894 in Patients With Major Depressive Disorder With Inadequate Response to Antidepressants.Status: Completed, Estimated PCD: 2024-01-10
Product
QuetiapineProduct
BI 1358894Clinical trial
A Phase II, 6-week, Multicenter, Randomized, Double Blind (Patient and Investigator) or Masked, Placebo Controlled, Dose-finding Trial to Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral BI 1569912 as Adjunctive Therapy in MDStatus: Recruiting, Estimated PCD: 2025-08-12
Product
BI 1569912Product
SeltorexantClinical trial
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant TherapyStatus: Terminated, Estimated PCD: 2022-05-24
Clinical trial
A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Subjects Assessed to be at Imminent Risk for SuicideStatus: Completed, Estimated PCD: 2023-03-31
Product
MidazolamProduct
EsketamineProduct
IntranasalProduct
JNJ-67953964Clinical trial
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects With Major Depressive DisorderStatus: Completed, Estimated PCD: 2020-05-06
Product
VortioxetineClinical trial
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDDStatus: Completed, Estimated PCD: 2019-07-30
Clinical trial
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant TherapyStatus: Completed, Estimated PCD: 2019-01-12
Clinical trial
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of AgeStatus: Terminated, Estimated PCD: 2022-03-25
Product
REL-1017Clinical trial
A 6-Month, Multicenter, Double-Blind, Randomized, Flexible-Dose, Parallel-Group Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant TherapyStatus: Completed, Estimated PCD: 2019-06-13
Product
Quetiapine XRProduct
JNJ-42847922Clinical trial
An Eight-week, Randomized, Double-blind, Two Parallel Groups, Study to Assess Clinical Response of Duloxetine 60 mg and 120 mg Per Day in Patients Hospitalized for Severe DepressionStatus: Completed, Estimated PCD: 2008-08-26
Clinical trial
A Multicentric, Randomized, Double-Blind, Placebo- and Positive-Controlled 4-way Crossover Study to Evaluate the Effects of Single and Repeated Administration of Oral Seltorexant as an add-on Medication to an Antidepressant on On-Road Driving Performance in Participants With Major Depressive DisorderStatus: Completed, Estimated PCD: 2023-03-16
Product
ZopicloneClinical trial
A Phase II 6-week, Randomized, Double-blinded, Placebo Controlled, Parallel Group Decentralised Clinical Trial to Evaluate Efficacy and Safety of Oral BI 1358894 in Patients With Major Depressive Disorder With Inadequate Response to AntidepressantsStatus: Terminated, Estimated PCD: 2022-04-19
Clinical trial
Interventional, Randomized, Double-blind, Placebo-controlled, Active-reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years, With Major Depressive Disorder (MDD)Status: Completed, Estimated PCD: 2022-01-21
Clinical trial
An Exploratory, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Subjects With Major Depressive DisorderStatus: Completed, Estimated PCD: 2019-04-29
Product
FluoxetineClinical trial
Randomized, Double-blind (Patient, Investigator), Placebo-controlled, Parallel Group, Single Dosing Study on Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of BI 1569912 as Adjunctive Therapy in Patients With Major Depressive DisorderStatus: Completed, Estimated PCD: 2023-11-16
Product
SLS-002Clinical trial
A 2-part Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) Administered to Adults With Major Depressive Disorder at Imminent Risk of SuicideStatus: Completed, Estimated PCD: 2023-06-17
Clinical trial
Double-Blind, Randomized, Parallel-Group Study With Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant TherapyStatus: Completed, Estimated PCD: 2023-10-03
Clinical trial
The Role of Inflammation in Cognitive Dysfunction in Acute Depression as Determined by Experimental Inhibition of Tumor Necrosis Factor-alpha Signaling in a Randomized Controlled Trial.Status: Not yet recruiting, Estimated PCD: 2027-09-01
Product
InfliximabClinical trial
Brain Network Dynamics of Depression During Esketamine TreatmentStatus: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine ResponseStatus: Recruiting, Estimated PCD: 2032-12-01
Drug
KetamineProduct
PerampanelClinical trial
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy and an Open-labeled Long-term Safety Extension Treatment With SeltorexantStatus: Completed, Estimated PCD: 2023-04-25
Clinical trial
Effects of Pharmacological Dopamine Modulation on Motivation and Motor Function in Major Depression Characterized by Low-grade Inflammation.Status: Recruiting, Estimated PCD: 2025-10-01
Product
L-dopa/CarbidopaClinical trial
VA Aripiprazole vs. Esketamine for Treatment of Depression VAST-D IIStatus: Withdrawn, Estimated PCD: 2023-10-27
Product
AripiprazoleClinical trial
The Effects of Accelerated Intermittent Thetaburst Stimulation Followed by a Cognitive Control Training in Treatment Resistant Unipolar Depressed PatientsStatus: Completed, Estimated PCD: 2023-12-31
Product
SSRIClinical trial
Combining Data Sources to Identify Effect Moderation for Personalized Mental HealthStatus: Active (not recruiting), Estimated PCD: 2021-12-31
Clinical trial
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)Status: Recruiting, Estimated PCD: 2025-04-01
Product
PsilocybinProduct
Inactive PlaceboClinical trial
Precision Psychiatry: Anti-inflammatory Medication in Immuno-metabolic DepressionStatus: Recruiting, Estimated PCD: 2024-12-01
Product
CelecoxibDrug
VarlilumabClinical trial
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Study 1.1. (Pharmacological Manipulation)Status: Not yet recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Pilot, Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of a Cannabis-Infused Oil For Treatment of Insomnia in Major DepressionStatus: Recruiting, Estimated PCD: 2024-03-31
Product
25:1 CBD/THCProduct
5:1 CBD/THCClinical trial
Investigations on the Efficacy of Ketamine in Depression in Comparison to Electroconvulsive TherapyStatus: , Estimated PCD: 2025-12-01
Product
KetamineClinical trial
Synaptic Imaging and Brain Network Activity Following Ketamine in Treatment Resistant DepressionStatus: Recruiting, Estimated PCD: 2023-08-31
Clinical trial
Simvastatin add-on to Escitalopram in Patients With Comorbid Obesity and Major Depression: A Multicenter, Randomized, Double-blind, Placebo-controlled TrialStatus: Recruiting, Estimated PCD: 2025-02-01
Product
SimvastatinClinical trial
A Short-term Exploratory Study to Evaluate Safety, Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to SSRI Monotherapy and PsychotherapyStatus: Terminated, Estimated PCD: 2024-04-08
Clinical trial
A Randomized, Double-Blind, Support-of-Concept Phase 2 Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)Status: Completed, Estimated PCD: 2022-06-28
Product
NiacinClinical trial
A Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyStatus: Recruiting, Estimated PCD: 2024-09-18
Product
AticaprantClinical trial
A Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyStatus: Recruiting, Estimated PCD: 2024-10-17
Clinical trial
An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)Status: Recruiting, Estimated PCD: 2025-10-22